Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > I would like to see…
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(93)
•••
Comment by lovingoldon Dec 15, 2022 4:33pm
133 Views
Post# 35174329

RE:RE:RE:RE:RE:I would like to see…

RE:RE:RE:RE:RE:I would like to see…our hope is the
1. XB3 is monotized...
Of course it will be monitized in several possible ways:
a/ by a sale or partnership of the xB3-001 program (Herceptin for brain cancer)
b/ moving internal programs such as xB3-008 (Hunter Syndrome) into the clinic
c/ partners such as Chiesi, Neuramedy, Johnson & Johnson (Janssen) eventually completing their studies and achieving milestones. And just because these milestones have not been hit yet doesn't mean they won't be in the future. Studies can take longer than planned, can morph into bigger studies, or involve delays that have nothing to do with Bioasis or xB3.

2. The FDA glioplastoma "fast track trial is successful".
Very true. And rare disease druges have exclusivity for 7+ years and high price tags so are very, very valuable profit machines for pharma.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities